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Nonalcoholic fatty liver disease (NAFLD) is currently the most common liver disease worldwide, both in adults and in children. NAFLD is characterized by
aberrant lipid storage in hepatocytes (hepatic steatosis) and inflammatory progression to nonalcoholic steatohepatitis. Evidences so far suggest that intrahepatic
lipid accumulation does not always derive from obesity. Gut microbiota has been considered as a regulator of energy homeostasis and ectopic fat deposition,
suggesting its implications in metabolic diseases. Probiotics are live microbial that alter the enteric microflora and have beneficial effects on human health.
Although the molecular mechanisms of probiotics have not been completely elucidated yet, many of their effects have proved to be beneficial in NAFLD,
including the modulation of the intestinal microbiota, an antibacterial substance production, an improved epithelial barrier function and a reduced intestinal
inflammation. Given the close anatomical and functional correlation between the bowel and the liver, and the immunoregulatory effects elicited by probiotics,
the aim of this review is to summarize today's knowledge about probiotics in NAFLD, focusing in particular on their molecular and biochemical mechanisms, as
well as highlighting their efficacy as an emerging therapeutic strategy to treat this condition.
© 2011 Elsevier Inc. All rights reserved.Keywords: Probiotic; NAFLD; Insulin resistance; Inflammation; Therapy1. Introduction
Intestinal microflora has been first claimed to have a beneficial
influence on human health over a century ago, and the ensuing
research has by now soundly confirmed this concept. In the gut live
about 1014 bacterial cells, including up to 2000 species dominated by
anaerobic bacteria [1]. Intestinal microflora benefits from a constant
nutrient flow, a stable temperature and appropriate niches for various
metabolic requirements provided by the intestinal environment.
Likewise, the host benefits from the ability of the intestinal microflora
to synthesize vitamin K, exert trophic effects on intestinal epithelial
cells, salvage energy from unabsorbed food by producing short-chain
fatty acids (SCFA), inhibit the growth of pathogens, sustain intestinal
barrier integrity, maintain mucosal immune homeostasis and partic-
ipate to the xenobiotic metabolism system [2,3]. Probiotics are live
microbes able tomodulate the intestinalmicroflora and enhance body
health. At birth, the gastrointestinal tract is a sterile environment.
Within a few months after birth, a relatively stable microbial
population is established [3,4]. This abundant, diverse and dynamic
intestinal microflora normally lives in a complex, symbiotic relation-⁎ Corresponding author. Tel.: +39 81678413; fax: +39 81678403.
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representative bacteria among phyla found in the human colon, and
include Clostridia and lactic acid bacteria (LAB), and Bacteroidetes
[3,5]. However, several factors, such as age, diet, hygienic habit,
infection and antibiotic therapy, can modify the microbiota compo-
sition. Recently, gut microbiota has been considered as a regulator of
energy homeostasis and ectopic fat deposition, evidencing its
implications in metabolic diseases [6,7]. In particular, obese people
were shown to have lower Bacteroidetes and more Firmicutes in their
distal gut compared to lean control, and this alteration was abolished
after diet-induced weight loss [8]. Moreover, high-fat-fed animals
present gut microbiome with an increased number of transport
proteins and enzymes involved in absorption and fermentation of
simple sugars and host glycans. In return, these substances can be
more utilized for hepatic lipogenesis by increasing the capacity of
hosts to harvest energy from their diet [9]. Moreover, in healthy
subjects, the microbiote suppresses the expression of a fasting-
induced adipocyte factor (Fiaf, also known as angiopoietin-like
protein 4), a lipoprotein lipase inhibitor, which is produced not only
by the intestine, but also by liver and adipose tissue, and thereby
being an important regulator of peripheral fat storage [10].
The majority of patients with nonalcoholic fatty liver disease
(NAFLD) are either overweight or obese, and there is convincing
evidence that NAFLD is a component of the metabolic syndrome [11].
NAFLD is currently themost common liver disease worldwide, both in
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in hepatocytes (hepatic steatosis) and an inflammatory progression
to nonalcoholic steatohepatitis (NASH). Pathologically, there are
several patterns of disease that resemble the alcoholic liver disease,
but the sine qua non condition for NAFLD recognition is the
macrovesicular steatosis or fatty liver. Simple steatosis remains a
benign process in most affected people and seems to be well tolerated
[12,13]. However, some patients develop superimposed necroin-
flammatory activity with a nonspecific inflammatory infiltrate and
hepatocyte ballooning with Mallory's hyaline, which are the driving
force for the development of fibrosis, as observed in NASH [14]. Likely,
a minority of these patients develop cirrhosis, which may become
complicated by hepatocellular carcinoma. Probiotics have been
proposed in the treatment and prevention of many conditions. The
mechanisms of these effects are multiple, the vast majority being
related to the regulation of the immune system. Given the close
anatomical and functional correlation between the bowel and the
liver, and the immunoregulatory effects elicited by probiotics, the aim
of this review is to summarize the probiotics research in NAFLD,
specifically focusing on their molecular and biochemical mechanisms
and highlighting their efficacy as an emerging therapeutic strategy to
treat this condition.
2. Gut–liver axis
Due to its anatomical links to the gut, the liver is a major filter
organ and a first-line defense for the host. The liver is constantly
exposed to gut-derived bacterial fractions or metabolites, and it is an
important site for bacterial phagocytosis and clearance, as it hosts
more then 80% of the body's macrophages. In particular, Kupffer cells,
the resident macrophages of the liver, effectively limit the amount of
endotoxin and phagocyte bacteria carried through the portal vein,
thus playing a pivotal role in the clearance of systemic bacterial
infections [15]. Toll-like receptors (TLRs) recognize pathogen-
associated molecular patterns (PAMPs) to detect the presence of
pathogens. Even low amounts of PAMPs, such as lipopolysaccharide
(LPS), lipopeptides, unmethylated DNA and double-stranded RNA,
evoke intense inflammatory reactions.
Considering that the gut hosts more than 99% of the bacterial mass
in the body, intestinal microbiota is the principal source of bacterial-
derived PAMPs both in health and disease. In addition to their role in
innate immunity, TLRs also play a major role in the regulation of
inflammation. Several TRL endogenous ligands, termed damage-
associated molecular patterns, act as a signal of the presence of
necrosis and subsequent trigger of inflammation [16–18].
The healthy liver contains low mRNA levels of TLRs (TLR1, TLR2,
TLR4, TLR6, TLR7, TLR8, TLR9, TLR10) and signaling molecules (i.e.,
CD14, MD-2 and MyD88) as compared with other organs, suggesting
that the low expression of TLR signaling molecules may contribute to
the high tolerance of the liver to TLR ligands deriving from the
intestinal microbiota [19,20].
In chronic liver diseases, for instance, cirrhosis, structural
changes of the intestinal mucosa (e.g., loss of tight junctions,
widening of intercellular spaces, vascular congestion, defects in the
mucosal immune system) promote the loss of the barrier function
and allow for translocation of bacteria and bacterial PAMPs [20].
Many pro-inflammatory effects of PAMPs are a consequence of TLR-
induced secretion of inflammatory mediators, such as tumor
necrosis factor (TNF)-α and interleukin (IL)-1β, as demonstrated
in vitro and in vivo [21].
The gut–liver axis is indicative of a tight linkage between the
health of the intestinal tract and that of the liver. In fact, there is
growing evidence of how alteration of the gut microflora dysbiosis
may affect liver pathology. An altered intestinal bacterial flora
because of stress or wrong nutritional habits could play an importantrole in the pathogenesis or the development of NAFLD. On the basis
that a shift in the gut microbiota enteric profile, due to bacterial
overgrowth, may contribute to the pathogenesis of NAFLD, treat-
ments able to manipulate enteric flora, such as probiotics or
prebiotics, have been proposed.
Normally, intestinal anaerobic bacteria outnumber aerobic bacte-
ria, the latter being responsible for bacterial translocation. Thus,
anaerobic bacteria, suppressing the colonization and growth of
potentially invasive microbes, exert an important role in maintaining
gastrointestinal health and in reducing the translocation of poten-
tially dangerous microbes. Conversely, selective elimination of
anaerobic bacteria promotes intestinal bacterial overgrowth and
translocation. Gram-negative bacteria such as Escherichia coli, Kleb-
siella pneumoniae, enterococci and streptococci not only represent the
species that are most proficient at translocation but also cause the
large majority of infections in patients with cirrhosis [22].
3. Key features of NAFLD: insulin resistance and inflammation
Insulin resistance (IR) plays a crucial pathophysiological role in the
development and progression of NAFLD. It is increasingly recognized
that free fatty acids (FFA) and soluble mediators, synthesized from
immune cells and adipose tissue, are crucially involved in regulating
insulin action and NAFLD occurrence [23,24]. The central role of IR in
liver diseases is further suggested by evidence that it is present also in
nonobese, nondiabetic subjects withNAFLD [25]. SubjectswithNAFLD
and IR present an impairment in muscle glucose uptake, an alteration
in suppression of hepatic endogenous glucose production induced by
insulin [25,26] and a high lipolytic effect in the adipose tissue resulting
in an increased FFAs release [27]. The importance of visceral fat in the
pathogenesis of hepatic IR and steatosis has been widely demonstrat-
ed in preclinical and clinical studies [28]. In particular, in an animal
model of inherited leptin resistance, the leptin-receptor-deficient
Zucker (fa/fa) rat, the surgical resection of intra-abdominal fat depots
reverses both hepatic IR and steatosis [29]. In humans, a clear
relationship exists between hepatic IR and visceral fat leading to
altered adipokine production and increased FFAs [30,31]. The
enlargement of the adipose tissue, and in particular visceral fat, has
been associated with a tissue inflammation characterized by a
decreased release of insulin-sensitizing and anti-inflammatory cyto-
kines, and an increased expression of pro-inflammatory molecules,
which modify adipokine secretion [31]. Subjects with NAFLD exhibit
decreased adiponectin levels [32], which are correlated negatively
with the hepatic triglyceride content. Interestingly, although the
three-dimensional structure of adiponectin closely resembles that of
TNF-α, these two proteins have completely opposite effects [33]. Both
in vivo and in vitro experiments demonstrated that the production
and function of adiponectin andTNF-α are inversely correlated in their
target tissues [34]. Administration of adiponectin into mice has been
shown to produce beneficial effects on lipid metabolism, such as
enhancing lipid clearance from plasma and increasing fatty acid β-
oxidation in muscle, whereas gluconeogenesis and de novo lipogen-
esis are decreased in the liver [35].
It has been demonstrated that the insulin-sensitizing effect of
adiponectin is mediated by an increase in fatty acid oxidation through
sequential activation of AMP kinase, p38 mitogen-activated protein
kinase and peroxisome proliferator-activated receptor (PPAR) α [36].
Other adipokines, such as leptin, visfatin and resistin, have also been
reported to be involved in hepatic triglyceride accumulation and
inflammation. However, the role of these factors and their interplay is
still to be elucidated [31].
It is well known that steatosis may interfere with sinusoid
microcirculation and hepatocellular clearance of microbial and host-
derived danger signals, enhancing responsiveness of Kupffer cells,
which critically contribute to progression of NAFLD [37]. Altered lipid
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sorting, leading to alternative signaling pathways activation, such as
nuclear factor-κB (NF-κB)/AP1 or interferon regulatory factor 3, and
promoting differential gene transcription. These differential path-
ways were found to be similar not only in Kupffer cells and hepatic
stellate cells but also in other hepatic nonimmune cell populations,
including hepatocytes, biliary epithelial and endothelial cells [18,19].
Additional factors appear to interact with adiponectin to regulate
the hepatic triglyceride content. Among these, PPARs that belong to
the nuclear receptor superfamily impact on multiple processes
involved in lipid trafficking and metabolism, and fuel partitioning
[38]. In particular, PPARα regulates mitochondrial and peroxisomal
fatty acid β-oxidation pathways by modulating many genes encod-
ing the enzymes involved in these processes (i.e., acyl-CoA
synthetase, carnitine palmitoyl transferase I and very-long-chain
acyl-CoA dehydrogenase).
Loss or reduction of PPARα expression, in KOmice or in animal fed
a methionine–choline-deficient diet or a high-fat diet (HFD), both
result in hepatic steatosis [39–41]. In nutritional NAFLD models, the
administration of a potent PPARα agonist or probiotics is found to
improve the hepatic steatosis. These findings suggest that under
conditions of an increased hepatic fatty acid influx, or a decreased
hepatic fatty acid efflux, PPARα activation prevents the accumulation
of triglycerides by increasing the rate of fatty acid catabolism [41,42].
A growing body of the literature implicates PPARs in the
pathogenesis and treatment of NAFLD, linking PPARα and PPARγ to
NAFLD/NASH [43]. In fact, PPARγ is expressed at high levels in the
adipose tissue and plays a role in increasing insulin sensitivity, as well
as in promoting fatty acid uptake into adipocytes [44]. The clear effect
of PPARγ activation is the increase in the adipocyte triglyceride
storage, thus reducing delivery of fatty acids to the liver. Moreover,
PPARγ increases insulin sensitivity by up-regulating glucose trans-
porter 4, an insulin-dependent glucose transporter in the adipose
tissue and striated muscle, and by inducing expression of the c-Cbl
associated protein, which is involved in insulin signaling [45].
Additionally, in mouse models of IR, PPARγ activation attenuated
the induction of suppressor of cytokine signaling 3 (SOCS3), which is
involved in the development of IR [46]. PPARγ expression also might
reduce the hepatic inflammation by decreasing the expression of
proinflammatory cytokines, such as TNF-α [47]. Moreover, adipo-
nectin is up-regulated by PPARγ, thereby providing a connection
between the two receptor isotypes.
The complexity and the chronology of pathophysiological events
leading to the development of NAFLD/NASH are not fully understood.
The increased intrahepatic levels of FFAs provide a source of oxidative
stress, which is in part responsible for the progression from steatosis
to steatohepatitis and cirrhosis. FFAs may elicit hepatotoxicity by
several mechanisms, among others a direct cytotoxic effect [48], an
increased lysosomal permeability and TNF-α synthesis by hepato-
cytes [49]. TNF-α is a pleiotropic cytokine that activates several
signaling mechanisms leading to hepatocyte apoptosis, activation of
hepatic stellate cells and hepatic inflammatory cell recruitment. TNF-
α is also known to inhibit propagation of insulin/insulin receptor-
initiated signals by Ser307 phosphorylation and Tyr dephosphoryla-
tion of the insulin receptor substrate-1 [50]. Therefore, TNF-α
represents a crucial protagonist of IR that links the hormonal and
metabolic alterations to the inflammatory process. A part TNF-α, IL-6
is another mediator that relates obesity-induced inflammation to IR
[51]. High serum IL-6 level is associated with IR and NAFLD [52], and
the induction of SOCS3 in the liver may be an importantmechanism of
IL-6-mediated IR [53]. Finally, the inhibition of TNF-α and IL-6 may
limit NASH and/or IR [54].
Recently, we have also demonstrated the involvement of metallo-
proteinases (MMPs) in the evolution of the liver inflammatory
process induced by an HFD [41,55]. These MMPs degrade thebasement membrane and extracellular matrix, and facilitate leuko-
cyte migration and the release of TNF-α from its membrane-bound
form, thus contributing to steatosis progression.
4. Probiotics, prebiotics and symbiotics
4.1. Probiotics
A probiotic is usually defined as a live commensal microorganism
that, when consumed in adequate quantities, confers a health benefit
to the host (FAO/WHO 2001). Criteria for designating a commensal
strain as a probiotic include a nonpathogenic, human origin; acid and
bile resistance; survival of gastrointestinal transit; production of
antimicrobial substances; and immune modulator activity [56–59].
The main probiotics on the market are lactobacilli, streptococci and
bifidobacteria, which are normal constituents of the human gastro-
intestinal microflora (Table 1). The first two ones belong to a large
group of bacteria designated as LAB [60]. LAB are described as Gram-
positive, nonsporing, anaerobic cocci or rods, and traditionally have
become associated with the genera Lactobacillus, Leuconostoc, Pedio-
coccus and Streptococcus [61]. This denomination emphasizes the
commercially important aspect of their metabolism, since they
produce lactic acid as the major end product during the fermentation
of carbohydrates. The genus Bifidobacterium is unrelated to LAB
phylogenetically, and the Bifidobacterium species use a unique
metabolic pathway for sugar metabolism. However, they are often
considered to be LAB and probiotics because of their documented
health-promoting effects [62].
Recent studies have demonstrated that beneficial effects were
achieved not only by live bacteria but also by heat-inactivated or
gamma-irradiated not viable bacteria, isolated bacterial DNA or
even probiotic-cultured media [63], presuming that probiotics can
“talk” to immune cells recognizing directly specific receptors or
that are otherwise sensitive to probiotic-derived products (e.g.,
metabolites, cell wall components, DNA). The field instead needs
to consider specific immunological applications, whether prophy-
lactic or therapeutic, and then proceed to address mechanisms by
which ingested probiotic organisms might be used to prevent or
treat several disorders.
4.2. Prebiotics
Prebiotics are indigestible carbohydrates that stimulate the
growth and the activity of beneficial bacteria, particularly lactobacilli
and bifidobacteria [64]. Many years ago, the prebiotic lactulose has
been shown to improve symptoms in liver patients increasing the
numbers of bifidobacteria [65], and today it is of common use in these
patients [66]. Oligosaccharides that are contained in human milk are
considered to be the prototype of prebiotics, since they have been
shown to facilitate the growth of bifidobacteria and lactobacilli in the
colon of breast-fed neonates [67,68]. Any food that reaches the colon
other than nondigestible carbohydrates, such as peptides and
proteins, as well as certain lipids, is a potential prebiotic. Fructooli-
gosaccharides (FOS) consist of short- andmedium-length chains of β-
D-fructans in which fructosyl units are bound by a β 2-1 linkage, with
the degree of polymerization varying between 2 and 60 (inulin) or 2
and 20 (oligofructose) [69]. Because of the presence of the β-linkages,
FOS are indigestible in the upper gastrointestinal tract. Consequently,
they enter the cecum/large bowel as intact, and here they are largely
fermented to SCFA (mainly acetate, propionate and butyrrate and
other metabolites, e.g., lactate) and cause proliferation of selected
anaerobic bacteria, mostly bifidobacteria [69,70]. Thus, FOS including
inulin, other oligosaccharides, lactulose, resistant starch and dietary
fibers have been shown to promote a probiotic response [64].
Previously, it was also demonstrated that FOS modifying the gene
Table 1
Main probiotics used in commercial preparations
Lactobacilli L. acidophilus, casei, delbrueckii subsp. bulgaricus, reuteri, brevis,
cellobiosus, curvatus, fermentum, plantarum, paracasei, rhamnosus
(GG), salivarius, gasseri, johnsonii, helviticus, farciminis
Bifidobacteria B. bifidum, infantis, longum, thermophilum, adolescents, lactis,
animalis, breve
Fungi Saccharomyces cerevisiae and s boulardii
Others Streptococcus thermophilus, Enterococcus faecium, Lactococcus lactis,
Propionibacterium freudenreichii, Escherichia coli Nissle 1917,
Bacillus clausii, Bacillus oligonitrophilis
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synthesis [71], contributing to the decrease in triglyceride accumu-
lation in the liver. A number of studies provide novel insights on the
possible link between prebiotics and metabolic diseases, such as
obesity and IR [72,73]. Prebiotic supplementation is able to increase
plasmatic gut peptide concentrations (glucagon-like peptide 1 and
peptide YY), which may contribute in part to the changes in satiety
and postprandial glycemic response in healthy subjects [74]. A
functional food approach has been utilized to add FOS, primarily
inulin, to products (cereals, biscuits, infant foods, yogurts, breads and
drinks) or to dietary supplements at concentrations at which a
prebiotic effect may occur [75].
Indeed, the modification of intestinal microflora (increase in
bifidobacteria and subsequent reduction in Enterobacteriaceae)
contributes to a reduction in fecal pH, which results in a minor rate
of ammonia absorption and in a lower amount of total ammonia into
the bloodstream. Considering all this evidence, it is logical to assume
that also the prebiotics would be good candidates to protect the liver
in individuals with fatty liver and other liver problems.
4.3. Symbiotics
The term symbiotic is used “when a product contains both
probiotics and prebiotics” [70]. For example, the symbiotic combina-
tion of a specific oligofructose-enriched inulin and Lactobacillus
rhamnosus GG and Bifidobacterium lactis Bb12 for 12 weeks caused a
16% and 18% increase in the numbers of Lactobacillus and Bifidobac-
terium, respectively, and a 31% decrease in the numbers of Clostridium
perfringens [76]. Recent in vitro studies have confirmed that symbiotic
wasmore effective than prebiotics or probiotics in modulating the gut
microflora [77].
5. Biological and molecular basis of probiotic action in NAFLD
Clinical and experimental studies suggest that probiotics differ
greatly in their effects and mechanisms of action. Significant
differences exist, not only among the probiotic species but also within
the same strain. The understanding of the various mechanisms of the
probiotic action is crucial for the establishment of definitive selection
criteria for certain strains or combination of strains in specific clinical
conditions. Although the molecular mechanisms of probiotic are not
fully elucidated, many effects may result beneficial in NAFLD,
including themodulationof the intestinalmicrobiota, the antibacterial
substance production, the epithelial barrier function, intestinal
inflammation or the immune system (Fig. 1).
5.1. Modulation of the intestinal microflora composition and
antibacterial factor production
Probiotic can limit the role of bacterial pathogens in NAFLD
through at least two mechanisms: the exclusion or inhibition of
invading bacteria and the production of antimicrobial factors.
Nonspecific antimicrobial substances include SCFAs [78], hydrogenperoxide [79], bacteriocins, bacteriocin-like inhibitory substances and
bacteriophages [80].
SCFA are produced during the anaerobic metabolism of carbohy-
drates, especially by strains of lactobacilli, and have an important role
in decreasing pH and inhibiting the growth of a wide range of Gram-
negative pathogenic bacteria. The inhibition of microbial growth by
organics may be due to the ability of these acids to pass across the cell
membranes, dissociate in the more alkaline cell environment and
acidify the cytoplasm [81]. Alternatively, fermentation acid dissocia-
tion in themore alkaline interior causes an accumulation of the anionic
species, and this accumulation is dependent on the pH gradient (delta
pH) across the membrane and may cause osmotic stress [82]. In
microbial fermentor systems, pH modification may lead to a shift in
the composition of the microbiota community [83], limiting the
populations of certain gut pathogens [84]. Bacteriophages are highly
specific and can be active against a single strain of bacteria. The two-
component lantibiotics, a class of bacteriocins produced by Gram-
positive bacteria, such as Lactococcus lactis, are small antimicrobial
peptides [85]. These peptides have been found to be active at
nanomolar concentrations to inhibit multidrug-resistant pathogens
by targeting the lipid II component of the bacterial cell wall [86]. Other
non-lanthionine-containing bacteriocins are small antimicrobial pep-
tides produced by lactobacilli. These peptides have a relatively narrow
spectrum of activity and are mostly toxic to Gram-positive bacteria,
including Lactococcus, Streptococcus, Staphylococcus, Listeria and
mycobacteria. The main mechanisms of bacteriocin action are based
on forming pores in the cytoplasmic membrane of sensitive bacteria
and interfering with essential enzyme activities. In addition, several
strains of Bifidobacteria have been found to produce bacteriocin-like
compounds toxic to both Gram-positive and Gram-negative bacteria
[87]. Bifidobacteria and lactobacilli can adhere to intestinal epithelial
cells through surface-expressed proteins [88,89]. In particular, Lacto-
bacillus casei binds to extracellular matrix components, such as
collagen, fibronectin or fibrinogen [90]. Moreover, apart from their
antimicrobial effects, some secreted probiotic factors are also able to
inhibit the binding of pathogenic bacteria to the specific receptors
expressed on the epithelium surface [88]. Several strains of lactobacilli
and bifidobacteria are capable to compete with and displace
pathogenic bacteria, including Bacteroides vulgatus, Clostridium histo-
lyticum, Clostridium difficile, Enterobacter aerogenes, Listeria mono-
cytogenes, Staphylococcus aureus, Salmonella enterica, Yersinia
enterocolitica [91], enterotoxigenic Escherichia coli [92,93] and
enteropathogenic Escherichia coli [94], even if the pathogens have
attached to intestinal epithelial cells prior to probiotic treatment [91].
In this context, recent studies regarding proteinase treatment and
carbohydrate competition have confirmed that the probiotic binding
to intestinal epithelial cells is mediated by lectin-like adhesion and
proteinaceous cell surface components [95,96], which are the same
receptors mediating pathogenic bacteria binding to intestinal epithe-
lial cells. For example, lactobacilli and bifidobacteria establish
mannose andGalβ1-3GalNAc-specific adhesions to attach to intestinal
epithelial cells and mucus [95], competing with pathogens for lectin
binding sites of glycoconjugate receptors for intestinal adherence.
Therefore, the capability of probiotics to improve gut ecology and
microbial composition, in inhibiting pathogenic bacteria growth and/
or competing with and displacing pathogenic bacteria, is likely to
prevent small intestinal bacteria overgrowth.5.2. Modification of intestinal epithelial permeability and function
Probiotics are able to improve the nonspecific intestinal barrier
defense mechanism, modulating tight junctional protein mucins and
stimulating their production. These effects limit small intestinal
bacterial overgrowth and bacterial translocation. Both events are
Fig. 1. Mechanisms of action of probiotics. Specific mechanisms: involvement of probiotics in cell-mediated and humoral immune responses. Aspecific mechanisms: enhancement of
epithelial barrier function, competitive exclusion of bacteria along epithelium, modification of local microenvironment and reduction of intestinal inflammation. Th, T helper cell; Ig,
immunoglobulin; Treg, regulatory T cell; IL, interleukin; TGF, transforming growth factor; TNF, tumor necrosis factor; IFN, interferon; M, M cell; DC, dendritic cell; TJ, tight junction;
MΦ, macrophage; SCFA, short-chain fatty acid; NF-κB, nuclear factor-κB; ROS, reactive oxygen species.
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reduced endotoxemia [97].
The mucus layer covering the gastrointestinal mucosa is consid-
ered the first line of defense against mechanical, chemical or
microbiological aggressions arising from the luminal contents.
Indeed, the break of the mucus barrier in an inflamed colon has
been shown to allow bacterial adherence to the epithelial tissue [98],
and the removal of the mucus layer favors the penetration of high-
molecular-weight probes in the mucosa [99]. It has been demon-
strated that lactobacilli up-regulate the MUC2 and MUC3 mucins and
inhibit attachment of enterohemorrhagic Escherichia coli in vitro
[100], and that a probiotic mixture of lactobacilli and bifidobacteria
increase the secretion of mucin, stimulating MUC2 gene expression in
the rat colon in vivo [101].
Probiotics stimulate the production of SCFAs [102], which, in turn,
are able to modulate intestinal permeability as demonstrated under
several conditions, including antibiotic-associated colitis, inflamma-
tory bowel disease, colon cancer and hepatic encephalopathy.
Probiotic administration may potentially reduce bacterial metabo-
lites, which may be toxic to the intestinal epithelium, for instance
hydrogen sulfide and extracellular superoxide [103].
Lactobacillus GG, Bifidobacterium infantis, Bifidobacterium lactis
and Escherichia coli Nissle 1917 increase tight junction integrity,
preventing tight junction disruption. The biochemical pathways
mediating the probiotic effect on tight junction functions includeprotein kinase C and mitogen-activated protein kinase pathways, and
involve both the redistribution and altered expression of the tight
junction proteins occludin, ZO-1 and ZO-2, and claudins 1, 2, 3 and
4 [104,105].
5.3. Modification of endotoxemia
Besides the clear role played by endotoxin levels in alcoholic liver
injury, the involvement of endotoxemia in NAFLD has also been
addressed. The increase of endotoxemia and the induction of hepatic
TLR4 and TLR accessory molecules (MD-2 and CD14) were evidenced
in mice fed with a methionine–choline-deficient diet, suggesting that
TLR4 signaling is, indeed, important for the pathogenesis of NASH
[106]. Moreover, depletion of Kupffer cells lowered diet-induced
increases in TLR4 and TNF-α, indicating a crucial role for these cells in
mediating TLR4 signaling and transcription of cytokines. Our
preliminary data evidenced that rats fed with Surwit diet, a model
of IR and NASH, showed an increase in the expression of hepatic TLR4.
Indeed, the low physiological levels of these receptors are suggestive
of the high tolerance of this organ to intestinal bacteria and bacterial
PAMPs recognized as TLR ligands. In this model, a chronic treatment
with Lactobacillus paracasei (strain B21060) restores the low TLR4
expression in the liver, reducing inflammatory pathways downstream
the TLR4 signaling and subsequently delaying NAFLD development
(our unpublished data).
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Intestinal inflammation leads to an increase of mucosal perme-
ability and bacterial translocation. Several cytokines, such as TNF-α,
interferon (IFN)-γ, IL-4 and IL-13, have been shown to increase
permeability in vitro [107], altering tight junction morphology and
distribution [108], thereby creating a self-perpetuating vicious cycle
that amplifies bacteria translocation, and possibly, extraintestinal
inflammation and damage.
Within intestinal epithelial cells, the transcription factor NF-κB is a
master coordinator of immune and inflammatory responses to
pathogenic bacteria and other stress signals. However, most com-
mensal bacteria do not activate NF-κB, while some of them are able to
antagonize it within enterocytes by several mechanisms. In particular,
the nuclear export of the p65 subunit of NF-κB is likely to occur in a
PPARγ-dependent manner [109]. Soluble components from amixture
of commercially available probiotics, VSL#3 and Lactobacillus reuteri
inhibited the epithelial proteasome function, preventing the degra-
dation of IκB [108,110]. This event was accompanied by an increased
expression of nerve growth factor, which has anti-inflammatory
properties. This finding implicates a role for the enteric nervous
system in host microbial interactions.
A few probiotic bacteria, including the mixture VSL#3, Lactoba-
cillus reuteri, Lactobacillus salivarius UCC118 and Bifidobacterium
infantis 35624 have been shown to suppress IL-8 secretion from
intestinal epithelial cells in response to several pathogenic bacteria
[108,111]. This cytokine [112] transcriptionally regulated by NF-κB is
a potent neutrophil-recruiting and neutrophil-activating chemokine.
The anti-inflammatory effects of a number of probiotic bacteria
including Bifidobacterium infantis 35624 and Lactobacillus salivarius
UCC118 have been shown also to bemediated, though only in part, via
NF-κB [111]. Besides NF-κB pathway, other intracellular signal
transduction pathways have also been associated to the protective
effects mediated by probiotics. These include mitogen-activated
protein kinase, protein kinase B, activator protein-1 and PPAR-γ
pathways [113–115].
Apart from intestinal inflammation, small intestinal bacterial
overgrowth and translocation result in endotoxemia that directly
stimulates hepatic Kupffer cells to produce TNF-α and oxygen free
radicals [116,117]. The role of TNF-α in NAFLD has been well
documented and was strengthened by the improved liver function
with anti-TNF therapy [118,119]. TNF release, in fact, stimulates liver
fibrosis and increases lipid peroxidation, contributing to the patho-
genesis of fatty liver disease [120,121]. A study performed in ob/ob
mice, as a model of NAFLD, demonstrated an improvement in mice
treated with the probiotic mixture VSL#3, also related to a reduction
of TNF-α activity [119]. Similar data were obtained by our group in a
model of NAFLD induced by an HFD: we demonstrated the
antioxidative and anti-inflammatory effect elicited by VSL#3 in an
experimental model of NASH induced in young rats. This probiotic
mixture induced a decrease in the oxidative stress, evidenced through
the reduction of malondialdehyde, and protein nitrotyrosilated levels
in the liver. Moreover, VSL#3 exhibited an anti-inflammatory activity
by a reduction of NF-kB activation in the liver and, hence,
cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS)
expression. This effect was also evidenced by VSL#3 capability to
reduce hepatic TNF-α level, the key pathogenetic factor responsible
for the onset of NASH, and for restoring PPARα expression [41].
Another study measured the hepatic natural killer T (NKT)-cell
depletion in high-fat-fed animals. This diet induced the depletion of
NKT from the liver, leading to overproduction of TNF-α and causing
inflammation, IR and steatosis. VSL#3 significantly improved all these
parameters restoring insulin signaling [122]. Considering the anti-
inflammatory properties of more than 550 different LAB strains, a
new symbiotic composition was obtained, consisting of Lactobacillusplantarum, Lactobacillus paracasei subsp. paracasei, Lactococcus raffi-
nolactis and Pediococcus pentosaceus, plus four different fibers known
for their strong bioactivity: betaglucan, inulin, pectin and resistant
starch. This composition, Symbiotic 2000, was successfully investi-
gated in surgical operations such as liver transplantation, reducing
the problem of postoperative infections [123].5.5. Immune system modulation by probiotics
Commensal bacteria can modulate the immune system at both
local and systemic levels. Signals mediated by these bacteria are
essential for optimal mucosal and immune development, and to
maintain or restore gut integrity [124,125]. In the intestinal tract,
immunocytes, such as enterocytes, M cells and dendritic cells (DCs),
are constantly responding to intestinal bacteria. These cells express
pattern recognition receptors, such as TLRs, that engage bacterial
signals (LPS, lipotechoic acid, bacterial DNA and flagellin) and
contribute to the activation of transcription factors and proinflam-
matory cascade. Immune engagement and systemic immunologic
changes are associated with oral consumption of probiotics [126],
which share the same host–microbial signaling pathways of com-
mensal microbiota. In the intestine, probiotic bacteria are internalized
by M cells to interact with DCs and follicle-associated epithelial cells,
initiating responses mediated by macrophages and T and B lympho-
cytes [127].
DCs initiate immune responses in vivo by presenting antigens to T
cells and influence polarization of T-cell responses (Th1, Th2, Th3 or
regulatory T cells) through secretion of immunoregulatory cytokines.
Moreover, DCs contribute to oral tolerance induction by generating
regulatory T cells and IgA-producing B cells through production of
cytokines, such as IL-10 and transforming growth factor (TGF)-β [128].
Regulatory T cells produce high levels of IL-10 and suppress the
proliferation of effector T cells in an IL-10-dependent manner.
Different strains of lactobacilli and other probiotic bacteria can
modulate DCs function modulating cell maturation and the expres-
sion of regulatory cytokines, such as IL-10 [129,130].
DCs from different lymphoid compartments exhibit divergent
cytokine responses to probiotic and pathogenic bacteria [131]. Some
strains of probiotic bacteria, such as Lactobacillus casei or Lactobacillus
reuteri, but not Lactobacillus plantarum, can promote DCs to induce
tolerance driving the development of regulatory T cells [132].
Similarly, VSL#3 can ameliorate Th1 cell-mediated murine colitis,
by restoring cytokine balance through the induction of IL-10- and
TGF-β-bearing regulatory T cells [133].
Probiotics can interact either directly with DCs or indirectly, via
the action of M cells. Very recently, the ability of three lactobacilli
strains (plantarum, LGG and paracasei B21060) to activate DCs has
been evaluated. Lactobacillus paracasei B21060 has been identified as
the more immunomodulatory among the three strains, being able to
inhibit the inflammatory potential of pathogenic Salmonella and to
protect against experimental colitis [134].
Probiotics, in addition to facilitating cell-mediated immunity, are
able to promote humoral response. The administration of probiotic
bacteria leads to an increase in the levels of pathogen-specific IgA
[135], and IgA responses are enhanced in formula-fed infants
supplemented with probiotics as compared with infants receiving
placebo [136]. Noteworthy is the induction of IgA in the gut being
heavily dependent on TGF-β, and also closely involved in the
maturation of regulatory T cells [137]. In agreement with these
studies, a recent randomized, double-blind, placebo-controlled trial
has demonstrated that the administration of two probiotic bacteria,
Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis, in-
creased the proportion and activity of phagocytic and NKT cells, as
well as the levels of IgA in healthy adults [138,139].
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function by increasing the number of IgA-producing plasma cells, as
well as improving phagocytosis, and the proportion of Th1 cells and
NKT cells [140]. Some strains are more likely to have strong clinical
effects; among them are strains like Lactobacillus paracasei subsp.
paracasei, Lactobacillus plantarum and Pediococcus pentosaceus. In
particular, Lactobacillus paracasei has been shown to induce cellular
immunity and stimulate production of suppressive cytokines such as
TGF-β and IL-10, to suppress Th2 activity and CD4 T cells [141], as well
as splenocyte proliferation [142], and to decrease antigen-specific IgE
and IgG1 [143]. Lactobacillus paracasei was also shown to be the
strongest inducer of Th1 and repressor of Th2 cytokines [144].
Moreover, co-culturing LAB with human or rodent leukocytes has
been shown to augment the production of type II IFN-γ by mitogen-
stimulatedmononuclear cells, or to induce type I IFN-α production by
isolated macrophages [145,146]. Both interferons promote Th1-type
immune responses and reduce IgE production [147].
IL-12 has been shown to be an important pro-interferon cytokine
involved in the production of LAB-stimulated IFNγ [146]. IL-12 is
known to be an effective cytokine during the early differentiation of
Th0 cells, promoting development of Th1 lymphocytes and augment-
ing NKT cell function; both of these actions increase IFNγ-producing
capacity, limiting the overexpression of a Th2 phenotype. Moreover,
IL-12 has also been demonstrated to regulate IL-4 production, limiting
both the establishment andmaintenance of Th2-type responses [148].
In vitro studies have indicated that LAB are potent stimulants for
IL-12 production by intestinal mucosa or peripheral blood leukocytes
[149,150]. In addition, some lactobacillus strains stimulate the
production of IL-18 by human leukocytes [149]. In its turn, IL-18
acts synergistically with IL-12 to enhance IFNγ production and to
promote a Th1 phenotype [151]. Thus, the presumed scenario is that
immunoregulatory LAB stimulate the production of pro-interferon
monokines (IL-12 and IL-18) which, in conjunction with IFN-α,
induce production of IFNγ; this biases a developing T lymphocyte-
mediated immune response toward a Th1 phenotype and, more
interestingly, away from a pro-allergy Th2 phenotype [135].
The varying immunological effects of bacteria highlight the
differences arising when different cellular, fluid or tissue systems
are used. However, there appear to be different responses of different
bacterial strains even within one genus. All these observations need
to be considered to properly address the immunomodulation capacity
of probiotics.6. Probiotic efficacy in NAFLD: from animal models to
clinical evidences
Themajor difficulties in our knowledge about probiotics efficacy in
NAFLD derived from the different experimental models used and
bacterial strains tested (Table 2). Clinical research intomechanisms of
NAFLD development and progression is restrained by ethical
considerations, particularly with respect to obtaining liver and other
tissues, and by inadequate ability to delineate cause and effect from
complex pathology because of the many mechanisms involved. From
an experimental viewpoint, it is, therefore, attractive to use animal
models. Research models of NAFLD may be divided into two main
typologies, those caused by genetic mutation and those with an
acquired NAFLD phenotype [152–154].
The central feature of the “modern lifestyle” that predisposes to
overweight, obesity, IR and fatty liver disease is the constant caloric
overconsumption, also known as “overnutrition.” The latter has been
achieved in animal models in a number of different ways, including
forced feeding, administration of HFDs, the use of genetically
hyperphagic animals or a combination of these approaches. The
effects of administering an HFD to rodents can be highly variablebased on treatment duration, animal strain, percentage and nature of
fat added to diet.
The high percentage of fat contained in the diets may range
between 40% and 70%. The well- known study by Lieber and
colleagues [155] described the effects of feeding a liquid HFD to
Sprague–Dawley rats. High-fat-fed rats showed quickly extensive
mitochondrial abnormalities and dysfunction producing reactive
oxygen species with an array of responses that resulted in hepatocyte
injury and cell death, inflammation and fibrosis. Conversely, to better
study the relationship between the visceral adipose tissue and the
liver, it is possible to use a high-fat and calorie-solid diet [156], by
creating in several weeks a model of IR and NAFLD/NASH in
nongenetically modified animals [157]. This model is characterized
by visceral obesity, increased glucose and insulin levels, decreased
PPARα expression, and alterations in insulin signaling and hepatic
steatosis, leading to oxidative stress, necroinflammatory liver injury,
cell apoptosis and collagen deposition. On the other hand, different
diet manipulations have been shown to induce obesity and fatty liver
in a number of different strains and species of rodents, suggesting that
“overnutrition” with either carbohydrates (fructose and sucrose) or
fats (fatty acid and cholesterol) or both might play a role in the
genesis of obesity-related NAFLD.
The efficacy of probiotics in several experimental models of
NAFLD/NASH is reported in Table 2. As depicted, the most
characterized probiotic is VSL#3 mixture, active in several murine
models of HFD-induced NAFLD/NASH [41,119,122].
Li et al. [119] using ob/ob mice fed with an HFD provided first
evidence that manipulation of the intestinal flora in this experimental
model influences obesity-related fatty liver disease. In fact, VSL#3
similarly to anti-TNF-α antibodies improved liver histology, reduced
hepatic total fatty acid content and decreased serum alanine
aminotransferase (ALT) levels. These effects were associated with a
reduction in Jun N-terminal kinase and NF-κB activity, fatty acid β-
oxidation, and mitochondrial uncoupling protein-2 expression, all
being markers and factors characterizing IR. Subsequently, Ma et al.
[122] showed that oral VSL#3 treatment significantly improved the
HFD-induced IR and steatosis recovering hepatic NKT cell depletion.
Our research group also showed the efficacy of VSL#3 inNAFLD [41]. In
our study, the VSL#3 was able to ameliorate lipid profile and reduce
inflammation and oxidative damage, protein nitrotyrosilation, and
tissue TNF-α level, interfering with the key pathogenetic mechanisms
responsible for the onset of liver damage. We also demonstrated a
direct effect of VSL#3 in reducing inflammatory enzymes, such as iNOS
and COX-2, and restoring PPAR-α. The VSL#3 treatment also reduced
hepatic gelatinase activity of proMMP-2 and proMMP-9 in HFD-fed
rats [158]. Conversely, recent data have demonstrated that in another
model of NAFLD/NASH, VSL#3 attenuated fibrosis, reducing TGF-β and
collagen,α-SMA,MMPs expression but had no effect on liver steatosis
parameters and inflammation in methionine–choline-deficient diet-
fed mice [159]. These data are limited depending on the type of diet
used in these animal models. The major drawback of the methionine–
choline-deficient dietmodel is that of being associatedwith significant
weight loss, low serum leptin level and peripheral insulin sensitivity.
The severe atrophy of adipose tissue in methionine–choline-deficient
diet-fed mice suggests that in this model NASH reflects the associated
lipodystrophy rather than the metabolic syndrome [160].
Among probiotics, several strains of lactobacillus have shown to
have a protective effect on NAFLD [161–163]. In particular, an 8-week
oral treatment with Lactobacillus rhamnosus PL60 showed an
antiobesity effect and liver steatosis in diet-induced obesity mice.
Histopathological analysis of liver steatosis evidenced a lowered
grading score in diet-induced obesity mice receiving Lactobacillus
rhamnosus [162].
Moreover, a beneficial effect on liver alteration has been shown in
Lactobacillus acidophilus and Lactobacillus casei-treated mice fed with
Table 2
Effect of several probiotics in experimental models of NAFLD
Probiotic Experimental model Duration of therapy Results Reference
VSL#3 1.5×109 CFU/mouse/day Mice: ob/ob mice fed HFD 4 weeks Improved NAFLD histology and reduction in
hepatic total fatty acid content, and serum ALT
levels; amelioration of hepatic IR
[Li et al., 2003 [119]
Bacillus polyfermenticus SCD 3.1×106
CFU/day
Rats: high-fat and
high-cholesterol diet
6 weeks Reduction in plasma LDL, cholesterol, and hepatic
total cholesterol, and triglycerides
[Paik et al., 2005 [164]
Lactobacillus rhamnosus PL60
1.0×107–-1.0×109 CFU/mouse/day
Mice: HFD 8 weeks Resolution of hepatic steatosis (at higher dose) [Lee et al., 2006 [162]
Lactobacillus acidophilus and
Lactobacillus casei
Rats: high-fructose diet 8 weeks Reduced liver oxidative stress, improved IR [Yadav et al., 2007 [163]
VSL#3 1.5×109 CFU/mouse/day Mice: HFD 4 weeks Improved HFD-induced hepatic NKT cell
depletion, IR, hepatic steatosis and inflammation
[Ma et al., 2008 [122]
Lactobacillus plantarum MA2 1×1011
CFU/rat/day
Rats: cholesterol-enriched diet 5 weeks Reduction in liver and serum cholesterol and
triglycerides
[Wang et al.,2009 [161]
VSL#3 1.3×1010 CFU/kg Rats: HFD 4 weeks Amelioration of the hepatic inflammatory,
steatotic and peroxidative factors and reduction
in serum aminotransferase levels
[Esposito et al., 2009 [41]
VSL#3 in drinking water Mice: MCD 9 weeks No effect on MCD-induced liver steatosis and
inflammation, but amelioration of liver fibrosis
[Velayudham et al., 2009 [159]
Lactobacillus paracasei B21060 2.5×108
bacteria/kg/diet
Rats: 5 weeks Ameliorated steatosis, IR and decreased hepatic
inflammatory cytokines
Our unpublished data
MCD, methionine–choline-deficient.
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type 2 diabetes associated with IR, hyperinsulinemia and hypertri-
glyceridemia. Concomitantly, this overload of fructose to the liver
impairs the glucose metabolism and uptake pathways, leading to an
enhanced rate of de novo lipogenesis and inducing steatosis. In this
study, the two probiotics reported above delayed the onset of glucose
intolerance, reduced insulinemia and liver glycogen, and ameliorated
steatosis, reducing malonyldialdehyde and increasing gluthathione
content [163]. Using a cholesterol-enriched diet, Wang et al. [161]
demonstrated that the administration of Lactobacillus plantarumMA2
in rats, beyond the hypolipidemic effect, reduced both liver
cholesterol and triglycerides, and increased the number of fecal
lactobacilli and bifidobacteria. Similar data had been previously
observed when Bacillus polyfermenticus was administered in rat fed
with high-fat and high-cholesterol diet [164]. Recent unpublished
data by our laboratory support the beneficial effect of the symbiotic
formulation, named FLORTEC, containing viable lyophilized Lactoba-
cillus paracasei B21060 mixed with prebiotics (fructo-oligosacchar-
ides and arabinogalactane) on HFD-induced steatosis in young rats,
improving metabolic and inflammatory alterations.
Findings obtained so far suggest that probiotics may interfere with
the development of NAFLD/NASH at various levels (Fig. 2).
Despite the large number of preclinical studies about the use of
probiotics in the treatment of fatty liver disease, there are only two
pilot studies concerning their efficacy in NAFLD in humans (Table 3).
The first study [121] tested a mixture of probiotics (Lactobacillus
acidophilus, bifidus, rhamnosus, plantarum, salivarius, bulgaricus, lac-
tis, casei, breve) associated with prebiotics (FOS) and vitamins (B6, B2,
B12, D3, C and folic acid) in 10 patients with biopsy-proven NASH.
After 2 months of treatment, the treated patients showed a significant
improvement of liver damage and function tests, as well as a partial
persistence of the effect also after the end of treatment. Another pilot
study was carried out to evaluate the effects of probiotic therapy in
patients with chronic liver diseases [165]. Four groups of patients
were enrolled in the study: 22 NAFLD and 20 alcoholic liver cirrhosis
(AC) patients were compared to hepatitis C virus-positive patients
with chronic hepatitis, with and without liver cirrhosis. All patients
were treated for 3 months with VSL#3. In NAFLD and AC groups,
VSL#3 significantly improved plasma levels of malonyldialdehyde
and 4-hydroxynonenal, both markers of lipid peroxidation, whereas
cytokines (TNF-α, IL-6 and IL-10) were reduced only in AC patients. S-Nitrosothiols plasma levels were improved at the end of treatment in
all groups. These promising preliminary results are strongly indicative
of a great potential for the use of probiotics in the prevention and
treatment of NAFLD. However, as recently stated in a Cochrane meta-
analysis, further clinical studies are necessary to better define this
innovative strategy [166]. The large amount of experimental data on
probiotics effects that are nowadays available will very likely drive
the design of clinical trials in the next.7. Adverse effects of probiotics
Probiotics are generally regarded as safe. Side effects are rarely
reported and generally amount to little more than flatulence or
changes in bowel habits. A review outlining the safety of current
probiotic compounds has been published recently [167]. The use of
probiotics in immunocompromised or in critical ill patients should be
carefully evaluated to limit the risk of endocarditis or sepsis.
However, cases of infection caused by lactobacilli and bifidobac-
teria are extremely rare and are estimated to occur in approximately
0.05–0.4% of all cases of infective endocarditis and bacteremia [167].
One important clinical characteristic of lactobacilli is their
resistance to antibiotic vancomycin, empirically used against Gram-
negative bacteremia. Lactobacilli are considered as emerging patho-
gens in high-risk patients with neutropenia induced by chemother-
apy [168], in neonates submitted to surgery on a count of
cardiovascular disorders in pediatric patients submitted to gastro-
jejunostomy [169].
No increase in bacteremia caused by Lactobacillus species was seen
in Finland over the period of 1990–2000 despite an increased
consumption of Lactobacillus rhamnosus GG. A study on a long-term
consumption of Bifidobacterium lactis and Streptococcus thermophilus-
supplemented formula in children aged less than 2 years showed that
the product was well tolerated [170]. Complications of treatment
with probiotics have been observed in patients who are immuno-
compromised or in the intensive care setting. Saccharomyces
cerevisiae fungemia [171] and Lactobacillus bacteremia [169,172]
have been reported in patients with severe underlying illnesses.
Nevertheless, case reports have identified fungemia in two immuno-
suppressed patients [171] and exacerbation of diarrhea in two
patients with ulcerative colitis who consumed S. boulardii [173].
Fig. 2. Cellular mechanisms of probiotics in the liver. The reduction of gut-derived endotoxins leads to a decrease of Kupffer cell stimulation of TLR4 receptor and NF-κB-related gene
transcription, with a reduction of inflammation. Probiotics induce a reduction in profibrotic factors by stellate cells, improve insulin signaling, increase the rate of fatty acid catabolism
following PPARα activation and reduce FFAs afflux (see red cross). LPS, lipopolysaccharide; NF-κB, nuclear factor-κB; TLR, toll-like receptor; ROS, reactive oxygen species; iNOS,
inducible nitric oxide synthase; COX, cyclooxygenase; IL, interleukin; TNF, tumor necrosis factor; TGF, transforming growth factor; SMA, smooth muscle actin; MMPs,
metalloproteinases; TG, triglycerides; PPAR, peroxisome proliferator-activated receptor; FFAs, free fatty acids.
707A. Iacono et al. / Journal of Nutritional Biochemistry 22 (2011) 699–7118. Conclusions
The study of intestinal microbiota composition and role in
different pathological conditions has greatly helped our understand-
ing on the potential use of probiotics in liver diseases, from simpleTable 3
Clinical studies of probiotics on NAFLD
Probiotic Design Duration of t
LAB associated to prebiotics
(FOS) and vitamins (B6, B2,
B12, D3, C and folic acid)
Prospective, single-center, nonrandomized,
noncontrolled study pilot study.
Three groups of patients:
(1) n=12 patients with CHC
(2) n=10 patients with AC
(3) n=10 patients with NASH
2 months
VSL#3 Four groups of patients:
(1) n=22 NAFLD
(2) n=20 AC
(3) n=36 HCV-+ patients (in which n=20
CHC and n=16 CC) liver cirrhosis
3 months
CHC, chronic hepatitis C; CC, liver cirrhosis; NASH, patients with biopsy-proven nonalco
nitrosothiols. LAB mixture contains Lactobacillus acidophilus, bifidus, rhamnosus, plantaru
thermophilus; Bifidobacterium breve, longum, infantis; Lactobacillus acidophilus, plantarum, casesteatosis to cirrhosis. What is now clear is that not all probiotics may
have the same effect. High-quality preclinical studies and few
randomized controlled trials support the therapeutic use of probiotics
in liver diseases. Unfortunately, these data could not be extrapolated
for all probiotic compounds now available on the market. Theherapy Results Reference
Decreased serum ALT, γ-GT, MDA, 4-HNE
and TNF-α in NASH patients
[Loguercio et al., 2002 [165]
In NAFLD and AC groups, VSL#3 improved
plasma levels of lipid peroxidation markers:
MDA, 4-HNE.
In AC patients, cytokines (TNF-α, IL-6 and
IL-10) improved.
S-NO plasma levels improved in all groups.
[Loguercio et al., 2005 [121]
holic steatohepatitis; MDA, malondialdehyde; 4-HNE, 4-hydroxynonenal; S-NO, S-
m, salivarius, bulgaricus, lactis, casei, breve. VSL#3 mixture contains Streptococcus
i, bulgaricus.
708 A. Iacono et al. / Journal of Nutritional Biochemistry 22 (2011) 699–711rationale of the use of mixtures of bacteria is based on the possible
combination of different mechanisms of action of individual strains.
Additional carefully designed, mechanistic-based laboratory and
clinical studies need to be undertaken to provide scientific evidence
for the efficacy in NAFLD therapy of probiotics alone or in appropriate
synergistic combination between strains or with some prebiotics, that
is, lactulose. Keeping in mind “primum non nocere,” in the future,
nutrients containing pre-probiotics will very likely be considered a
new nutritional approach in NAFLD patients.Acknowledgments
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